Clinical Trial Update: Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Cediranib and Olaparib against Bevacizumab in patients with recurrent glioblastoma; results were posted in February 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Cediranib (Cediranib)
• Olaparib (Olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Glioblastoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-02-02